Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL versus RYANODEX.
CARISOPRODOL vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
250-350 mg orally 3 times daily and at bedtime
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Clinical Note
moderateCarisoprodol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate."
Clinical Note
moderateCarisoprodol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Ketoconazole
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Ketoconazole can be decreased when combined with Carisoprodol."